Tirzepatide vs semaglutide: doses compared
Tirzepatide and semaglutide are different medicines on different dose scales. Tirzepatide labels run from 2.5 mg to 15 mg a week. Semaglutide injection labels run from 0.25 mg to 2.4 mg a week, with 7.2 mg allowed for some adults.1, 3, 4 None of the four FDA labels gives a way to convert a dose of one into a dose of the other. This page sets the labels side by side and reports the two trials that compared the drugs directly. It does not tell you which to take.
At a glance
| Item | Tirzepatide | Semaglutide |
|---|---|---|
| Brand names | Mounjaro, Zepbound | Ozempic, Wegovy |
| Acts on | The GIP and GLP-1 receptors1 | The GLP-1 receptor4 |
| How it is given | Injection under the skin, once a week1, 2 | Injection under the skin, once a week. Wegovy also comes as a daily tablet3, 4 |
| Starting dose | 2.5 mg1, 2 | 0.25 mg3, 4 |
| Highest dose on a label | 15 mg in adults1, 2 | Ozempic: 2 mg.3 Wegovy: 2.4 mg, or 7.2 mg for some adults4 |
| Missed dose | Take within 4 days, otherwise skip1, 2 | Ozempic: take within 5 days.3 Wegovy: take if the next dose is more than 2 days away4 |
| Sold in vials | Yes, as well as pens1, 2 | No. Pens and prefilled syringes3, 4 |
The label schedules, brand by brand
| Brand | Start | Increases | Highest dose |
|---|---|---|---|
| Zepbound | 2.5 mg for 4 weeks, then 5 mg | By 2.5 mg, after at least 4 weeks on a dose | 15 mg1 |
| Mounjaro | 2.5 mg | By 2.5 mg, after at least 4 weeks on a dose | 15 mg in adults; 10 mg for ages 10 and older2 |
| Ozempic | 0.25 mg for 4 weeks, then 0.5 mg | To 1 mg, then 2 mg, each after at least 4 weeks | 2 mg3 |
| Wegovy injection | 0.25 mg for 4 weeks | 0.5 mg, 1 mg and 1.7 mg for 4 weeks each, then 2.4 mg or 1.7 mg | 2.4 mg; 7.2 mg for some adults4 |
Both drugs start low and step up about every four weeks. The shapes are alike. The milligram numbers are not on the same scale.
Full charts: tirzepatide, semaglutide, Zepbound, Mounjaro, Ozempic, Wegovy.
Is there a dose conversion between them?
Not an official one. We read all four labels for this page and found no table, ratio or instruction for converting between tirzepatide and semaglutide, or for switching from one to the other.1, 2, 3, 4
- They are different molecules. Tirzepatide activates two receptors, GIP and GLP-1. Semaglutide activates one, GLP-1.1, 4
- The trials compared set doses. They did not establish which doses are equal. In SURPASS-2, even the lowest tirzepatide dose tested, 5 mg, gave different average results from semaglutide 1 mg.2
- The labels do not recommend using them together. The Zepbound label says this about any GLP-1 receptor agonist, and the Wegovy label says it about any other GLP-1 receptor agonist.1, 4
A chart that lines up "5 mg of one equals so much of the other" is someone's estimate, not label information. How to move from one drug to the other is a decision for a prescriber.
Head to head in type 2 diabetes: SURPASS-2
| Weekly dose | A1C change | Reached A1C under 7% | Weight change |
|---|---|---|---|
| Semaglutide 1 mg | −1.9 | 79% | −5.7 kg |
| Tirzepatide 5 mg | −2.0 | 82% | −7.6 kg |
| Tirzepatide 10 mg | −2.2 | 86% | −9.3 kg |
| Tirzepatide 15 mg | −2.3 | 86% | −11.2 kg |
The trial enrolled 1,879 adults with type 2 diabetes who were already taking metformin. Average A1C at the start was 8.3%, and average weight was about 92 to 95 kg. It was open-label: participants knew which drug they were on, though not which tirzepatide dose.2
Semaglutide was given at 1 mg.2 The Ozempic label now goes up to 2 mg, a dose this trial did not include.3
Head to head in obesity: SURMOUNT-5
| Measure | Tirzepatide | Semaglutide |
|---|---|---|
| Average weight change | −20.2% | −13.7% |
| Average weight lost | 22.8 kg (50.3 lb) | 15.0 kg (33.1 lb) |
| Lost at least 10% | 81.6% | 60.5% |
| Lost at least 15% | 64.6% | 40.1% |
| Lost at least 20% | 48.4% | 27.3% |
| Lost at least 25% | 31.6% | 16.1% |
| Waist change | −18.4 cm | −13.0 cm |
| Stopped because of side effects | 6.1% | 8.0% |
The trial enrolled 751 adults with obesity, or with overweight and a weight-related condition, and without diabetes. Each took the highest dose they could tolerate: tirzepatide 10 mg or 15 mg, or semaglutide 1.7 mg or 2.4 mg. Most took the top dose at least once: 89.3% for 15 mg and 92.8% for 2.4 mg.5
The trial was open-label and sponsored by Lilly, the maker of tirzepatide. Lilly notes it was not powered to compare safety or tolerability, so the last row describes what happened and is not a tested difference.5
The 7.2 mg semaglutide dose now on the Wegovy label was not one of the doses in this trial.5, 4
How to read these results
- They are averages. Individual results varied in every group.
- The two trials studied different people. One enrolled adults with type 2 diabetes, the other adults without it. The numbers from one do not transfer to the other.
- Set doses were compared, not the drugs in general. A different pairing of doses could give a different gap.
- Both were open-label. Participants knew which drug they were taking.
- The source matters. The SURPASS-2 figures come from Lilly's FDA-reviewed label. The SURMOUNT-5 figures come from a Lilly press release; the paper is in the New England Journal of Medicine, and we could not open it.
- A trial dose is not a dose for you. It is a fact about the trial.
Side effects and warnings
All four labels carry a boxed warning about thyroid C-cell tumors seen in rodents. Whether either drug causes them in humans is unknown.1, 2, 3, 4
Stomach and bowel effects lead the lists of common side effects. Nausea, diarrhea, vomiting, constipation and abdominal pain appear on all four labels.1, 2, 3, 4 In SURMOUNT-5, Lilly reported that side effects were mainly stomach and bowel related and generally mild to moderate.5
This is not the full safety information. Read the Medication Guide that comes with your prescription.
Pens, vials and syringe units
- Tirzepatide: Zepbound and Mounjaro come as pens and as vials. A vial dose is drawn with a syringe: 0.5 mL from a single-dose vial, or 0.6 mL from a multi-dose vial.1, 2 See the tirzepatide mg to units chart.
- Semaglutide: Ozempic and Wegovy injections come as pens and prefilled syringes that deliver set doses, so there are no units to work out.3, 4
- Compounded versions: the FDA says compounded drugs are not FDA-approved.6 If you have one in a vial, the concentration on the pharmacy label decides the units. See the semaglutide mg to units chart.
Questions
Is there a tirzepatide to semaglutide dose conversion?
Not an official one. None of the four FDA labels gives a table, ratio or instruction for converting a dose of one drug into a dose of the other.
Is 5 mg of tirzepatide the same as 0.5 mg of semaglutide?
No label says so. The two are different molecules on different dose scales, and the trials compared set doses without establishing equal ones.
Are tirzepatide and semaglutide the same drug?
No. Tirzepatide is sold as Mounjaro and Zepbound and acts on the GIP and GLP-1 receptors. Semaglutide is sold as Ozempic and Wegovy and acts on the GLP-1 receptor.
Which led to more weight loss in a head-to-head trial?
In SURMOUNT-5, a 72-week trial in adults without diabetes, average weight change was 20.2% with tirzepatide and 13.7% with semaglutide, each at the highest tolerated dose. Individual results vary.
Which lowered A1C more in a head-to-head trial?
In SURPASS-2, a 40-week trial in adults with type 2 diabetes, A1C fell by 2.0 to 2.3 points on tirzepatide 5 to 15 mg and by 1.9 points on semaglutide 1 mg.
What is the starting dose of each?
The labels start tirzepatide at 2.5 mg once a week and semaglutide injection at 0.25 mg once a week.
What is the highest dose of each?
The tirzepatide labels go up to 15 mg a week in adults. Ozempic goes up to 2 mg a week. Wegovy maintenance is 2.4 mg a week, with 7.2 mg allowed for some adults.
Can tirzepatide and semaglutide be used together?
The Zepbound label does not recommend using it with any GLP-1 receptor agonist, and the Wegovy label does not recommend using it with any other GLP-1 receptor agonist.
Does this page tell me which one to take?
No. It reports what the labels and two trials say. Which medicine and dose suit you is a decision for your prescriber.
Sources
- Eli Lilly and Company. Zepbound (tirzepatide) prescribing information and Instructions for Use, revised 8/2026. uspl.lilly.com/zepbound (opens in a new tab)
- Eli Lilly and Company. Mounjaro (tirzepatide) prescribing information, revised 8/2026. uspl.lilly.com/mounjaro (opens in a new tab)
- Novo Nordisk. Ozempic (semaglutide) injection prescribing information, revised 05/2026, as posted by the FDA. accessdata.fda.gov (PDF) (opens in a new tab)
- Novo Nordisk. Wegovy (semaglutide) injection and tablets prescribing information, revised 06/2026, as posted by the FDA. accessdata.fda.gov (PDF) (opens in a new tab)
- Eli Lilly and Company, press release, 11 May 2025: SURMOUNT-5 results (NCT05822830). Company release. The results were published the same day in the New England Journal of Medicine (doi 10.1056/NEJMoa2416394), which we could not open, so the figures here are from the release. investor.lilly.com (opens in a new tab)
- U.S. Food and Drug Administration, "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss", content current as of 1 October 2026. fda.gov (opens in a new tab)
- Formulas and test cases: how the calculator math works.